Geert Jan Groeneveld

Neurologist-clinical pharmacologist, Professor of Clinical Neuropharmacology

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Geert Jan Groeneveld is a Professor of Clinical Neuropharmacology at Leiden University Medical Center in the Netherlands. His research focuses on clinical pharmacology in neurology, with recent work emphasizing the development of biomarkers and therapies for neurodegenerative disorders. He has published articles exploring machine learning techniques for monitoring central nervous system biomarkers, pharmacodynamic studies of novel compounds, and the challenges of genetic counseling for GBA1 variants in Parkinson's disease.

Articles (10)

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Wessel Kraaij

Professor

Leiden University

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Geert Jan Groeneveld

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Machine Learning Techniques for Developing Remotely Monitored Central Nervous System Biomarkers Using Wearable Sensors: A Narrative Literature Review

A Phase 1, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a highly selective NaV1.8 inhibitor, in Healthy Male Adults.

A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.

Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.

False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance.

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub> -receptor partial agonist for the treatment of dementias.

Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study.

Spotlight Commentary: Importance of dose redefining in the process of drug repurposing.

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

Experience in Genetic Counseling for <i>GBA1</i> Variants in Parkinson's Disease.

Collaborators (1)

Wessel Kraaij

Make your next move.